AZN Astrazeneca enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical Z
AZN Astrazeneca enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical Zegfrovy approved in US and China for locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations. Astrazeneca makes $600M upfront payment and up to $900M in milestone payments to Dizal Pharmaceutical. Zegfrovy demonstrates encouraging anti-tumour activity in NSCLC patients with various EGFR mutations.
AZN Astrazeneca enters exclusive global license agreement for novel oral EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical Zegfrovy approved in US and China for locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations.
Astrazeneca makes $600M upfront payment and up to $900M in milestone payments to Dizal Pharmaceutical.
Zegfrovy demonstrates encouraging anti-tumour activity in NSCLC patients with various EGFR mutations.